Canada

Health Canada is the federal department responsible for regulating health products in Canada, operating under the authority of the Food and Drugs Act (FDA) and its associated regulations, including the Medical Devices Regulations (SOR/98-282), the Food and Drug Regulations, and the Natural Health Products Regulations. Health Canada's Health Products and Food Branch (HPFB) oversees the review and authorization of pharmaceuticals, biologics, medical devices, in vitro diagnostics, and digital health technologies. The regulatory pathway varies by product class: medical devices are classified into four risk-based classes (Class I through IV), while pharmaceuticals and biologics follow New Drug Submission (NDS), Abbreviated New Drug Submission (ANDS), or Supplement pathways. Health Canada also operates priority review, Notice of Compliance with conditions (NOC/c), and Advance Consideration pathways to expedite access for products addressing serious or life-threatening conditions.

All submissions to Health Canada must be prepared in accordance with the International Council for Harmonisation (ICH) Common Technical Document (CTD) format, which is the accepted dossier standard for pharmaceutical and biologic applications. Foreign manufacturers are required to designate a Canadian Importer or Regulatory Correspondent and must comply with Good Manufacturing Practice (GMP) requirements, which Health Canada verifies through its own inspections or through mutual recognition agreements (MRAs) with regulatory partners such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Canada has also implemented Project Orbis and the Access Consortium (with Australia, Singapore, Switzerland, the UK, and others) to enable concurrent multi-jurisdictional reviews of innovative oncology and other priority products. Recent reforms include Health Canada's Agile Licensing initiative, which introduces rolling reviews, real-world evidence frameworks, and adaptive pathways to modernize authorization processes and reduce time to market for innovative health technologies.

Canada operates a decentralized public procurement model in which the thirteen provinces and territories hold primary constitutional responsibility for the delivery and financing of health services. Each province and territory maintains its own ministry of health, formulary committee, and procurement authority. Provincial drug benefit programs, such as the Ontario Drug Benefit (ODB), the Régie de l'assurance maladie du Québec (RAMQ), and BC PharmaCare, independently evaluate and list pharmaceutical products on their respective formularies, often after a national health technology assessment (HTA) recommendation from the Canadian Drug Agency (CDA-AMC, formerly CADTH). Medical devices and diagnostics are procured through regional health authorities and hospital group purchasing organizations (GPOs), with pan-Canadian procurement initiatives coordinated through the Canadian Collaborative Procurement Initiative (CCPI) and the pan-Canadian Pharmaceutical Alliance (pCPA), which negotiates manufacturer rebate agreements on behalf of participating public drug plans. The federal government directly funds and procures health products for specific populations, including First Nations and Inuit communities (through the Non-Insured Health Benefits program), federal inmates, and Canadian Armed Forces personnel.

The private sector plays a substantial role in Canadian health product procurement, with employer-sponsored and individual private insurance plans covering a significant share of pharmaceutical, medical device, and diagnostic spending outside of publicly funded programs. Canada does not rely materially on international donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, as it is a high-income donor country rather than a recipient. However, Canadian federal agencies and Crown corporations, including the Public Health Agency of Canada (PHAC) and the Strategic Innovation Fund, invest in domestic biomanufacturing capacity and pandemic preparedness procurement. Canada maintains a limited local manufacturing preference policy, but the federal government has signaled strategic intent to strengthen domestic production capacity for vaccines, biologics, and critical health supplies following supply chain vulnerabilities exposed during the COVID-19 pandemic, including investments through the Biomanufacturing and Life Sciences Strategy launched in 2021.